GlassScriptPhysician profile
Russell Dempsey
NPI 1720160872
$765.66
in general payments reported to CMS, 2019-2025
17 companies · $46.35 in 2025
The $46.35 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $609 · 2020: $96.32 · 2024: $13.83 · 2025: $46.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $60.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $60.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $172.40 | 2019-2025 | Airsupra |
| Novo Nordisk INC | $124.23 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $94.59 | 2019 | |
| Allergan, INC. | $56.96 | 2019-2020 | |
| Astellas Pharma US INC | $55.08 | 2019 | |
| Pfizer INC. | $45.94 | 2019 | |
| Amgen INC. | $39.82 | 2019 | |
| Lilly USA, LLC | $37.85 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $25.23 | 2019 | |
| Amarin Pharma, INC. | $17.03 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.22 | 2020 | |
| Supernus Pharmaceuticals, INC. | $14.87 | 2025 | Qelbree |
| Neos Therapeutics, LP | $14.19 | 2019 | |
| Abbvie INC. | $13.83 | 2024 | |
| Radius Health, INC. | $13.72 | 2025 | Tymlos |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $12.78 | 2019 | |
| Therapeuticsmd, INC. | $10.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Dempsey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.